AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Altisource Portfolio Solutions S.A. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Akero Therapeutics, Inc. (AKRO) Form 4 filing: Chief Scientific Officer Timothy Rolph reported option exercise and related share sales on 07/07/2025 under a Rule 10b5-1 trading plan adopted 08/12/2024.

  • Option exercise (Code M): Rolph exercised 12,500 options at an exercise price of $21.09, converting them into an equal number of common shares.
  • Open-market sales: Immediately after exercise he sold the same 12,500 shares in three tranches: 10,634 sh at a weighted-average $50.932, 1,825 sh at $51.996, and 41 sh at $52.617.
  • Net ownership: Shares directly held decreased from 179,624 to 167,124 (-7.0%). Derivative holdings stand at 19,933 vested, unexercised options (exercise price $21.09, expiring 12/12/2029).

The transaction yielded roughly $640k in gross proceeds while leaving Rolph with a substantial equity position. Because the exercise and sale amounts offset, cash was realized but the company’s share count is unchanged. The filing does not disclose motive beyond the pre-arranged trading plan and contains no operational or earnings information.

Akero Therapeutics, Inc. (AKRO) Comunicazione Form 4: Il Chief Scientific Officer Timothy Rolph ha riportato l'esercizio di opzioni e la vendita correlata di azioni il 07/07/2025, nell'ambito di un piano di trading Rule 10b5-1 adottato il 12/08/2024.

  • Esercizio opzioni (Codice M): Rolph ha esercitato 12.500 opzioni al prezzo di esercizio di 21,09$, convertendole in un pari numero di azioni ordinarie.
  • Vendite sul mercato aperto: Immediatamente dopo l'esercizio ha venduto le stesse 12.500 azioni in tre tranche: 10.634 azioni a un prezzo medio ponderato di 50,932$, 1.825 azioni a 51,996$ e 41 azioni a 52,617$.
  • Proprietà netta: Le azioni detenute direttamente sono diminuite da 179.624 a 167.124 (-7,0%). Le detenzioni di derivati ammontano a 19.933 opzioni maturate ma non esercitate (prezzo di esercizio 21,09$, scadenza 12/12/2029).

L'operazione ha prodotto circa 640.000$ di proventi lordi, lasciando comunque a Rolph una posizione azionaria significativa. Poiché gli importi di esercizio e vendita si compensano, è stato realizzato un incasso in contanti ma il numero totale di azioni della società non è cambiato. La comunicazione non specifica motivazioni oltre al piano di trading predefinito e non contiene informazioni operative o sugli utili.

Akero Therapeutics, Inc. (AKRO) Presentación del Formulario 4: El Director Científico Timothy Rolph reportó el ejercicio de opciones y la venta relacionada de acciones el 07/07/2025, bajo un plan de negociación Rule 10b5-1 adoptado el 12/08/2024.

  • Ejercicio de opciones (Código M): Rolph ejerció 12.500 opciones a un precio de ejercicio de 21,09$, convirtiéndolas en un número igual de acciones ordinarias.
  • Ventas en mercado abierto: Inmediatamente después del ejercicio vendió las mismas 12.500 acciones en tres tramos: 10.634 acciones a un precio promedio ponderado de 50,932$, 1.825 acciones a 51,996$ y 41 acciones a 52,617$.
  • Propiedad neta: Las acciones en propiedad directa disminuyeron de 179.624 a 167.124 (-7,0%). Las tenencias derivadas son 19.933 opciones ejercitables no ejercidas (precio de ejercicio 21,09$, vencimiento 12/12/2029).

La transacción generó aproximadamente 640.000$ en ingresos brutos, dejando a Rolph con una posición accionaria considerable. Debido a que los montos de ejercicio y venta se compensan, se obtuvo efectivo pero el número total de acciones de la empresa no cambió. La presentación no revela motivos más allá del plan de negociación preestablecido y no contiene información operativa o de ganancias.

Akero Therapeutics, Inc. (AKRO) Form 4 제출: 최고 과학 ì±…ìž„ìž� Timothy Rolphê°€ 2025ë…� 7ì›� 7ì¼ì— 2024ë…� 8ì›� 12ì� 채íƒë� Rule 10b5-1 거래 계íšì—� ë”°ë¼ ì˜µì…˜ 행사 ë°� ê´€ë � ì£¼ì‹ ë§¤ë„ë¥� 보고했습니다.

  • 옵션 행사 (코드 M): RolphëŠ� 행사 ê°€ê²� $21.09ì—� 12,500ê°œì˜ ì˜µì…˜ì� 행사하여 ë™ì¼í•� ìˆ˜ì˜ ë³´í†µì£¼ë¡œ 전환했습니다.
  • 공개 시장 매ë„: 행사 ì§í›„ ë™ì¼í•� 12,500주를 ì„� 차례ì—� ê±¸ì³ ë§¤ë„했습니다: 10,634주를 가중í‰ê·� $50.932ì—�, 1,825주를 $51.996ì—�, 41주를 $52.617ì—� 매ë„했습니다.
  • ìˆ� 소유ê¶�: ì§ì ‘ 보유 주ì‹ì€ 179,624주ì—ì„� 167,124주로 7.0% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. íŒŒìƒ ìƒí’ˆ 보유ëŠ� 행사 ê°€ê²� $21.09, 만기 2029ë…� 12ì›� 12ì¼ì¸ 19,933ê°œì˜ í–‰ì‚¬ 가능한 옵션입니ë‹�.

ì´ë²ˆ 거래ë¡� ì•� 64ë§� 달러ì� ì´� 수ìµì� 얻었으며, RolphëŠ� 여전íž� ìƒë‹¹í•� ì§€ë¶„ì„ ë³´ìœ í•˜ê³  있습니다. 행사와 ë§¤ë„ ìˆ˜ëŸ‰ì� ìƒì‡„ë˜ì–´ í˜„ê¸ˆì€ ì‹¤í˜„ë˜ì—ˆìœ¼ë‚˜ 회사ì� ì´� ì£¼ì‹ ìˆ˜ëŠ” ë³€ë™ì´ 없습니다. 제출 서류ì—는 사전 계íšë� 거래 ê³„íš ì™¸ì— ë™ê¸°ê°€ 공개ë˜ì§€ 않았으며, ìš´ì˜ ë˜ëŠ” ìˆ˜ìµ ì •ë³´ëŠ� í¬í•¨ë˜ì–´ 있지 않습니다.

Akero Therapeutics, Inc. (AKRO) Dépôt du Formulaire 4 : Le directeur scientifique Timothy Rolph a déclaré l'exercice d'options et la vente d'actions associée le 07/07/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 12/08/2024.

  • Exercice d'options (Code M) : Rolph a exercé 12 500 options au prix d'exercice de 21,09$, les convertissant en un nombre égal d'actions ordinaires.
  • Ventes sur le marché libre : Immédiatement après l'exercice, il a vendu les mêmes 12 500 actions en trois tranches : 10 634 actions à un prix moyen pondéré de 50,932$, 1 825 actions à 51,996$ et 41 actions à 52,617$.
  • Propriété nette : Les actions détenues directement ont diminué de 179 624 à 167 124 (-7,0%). Les avoirs dérivés comprennent 19 933 options acquises mais non exercées (prix d'exercice 21,09$, expiration 12/12/2029).

La transaction a généré environ 640 000$ de produit brut, tout en laissant à Rolph une position significative en actions. Comme les montants d'exercice et de vente se compensent, du liquidité a été réalisée mais le nombre total d'actions de la société reste inchangé. Le dépôt ne révèle pas de motif au-delà du plan de négociation préétabli et ne contient pas d'informations opérationnelles ou sur les bénéfices.

Akero Therapeutics, Inc. (AKRO) Form 4 Einreichung: Chief Scientific Officer Timothy Rolph meldete am 07.07.2025 die Ausübung von Optionen und den damit verbundenen Verkauf von Aktien im Rahmen eines am 12.08.2024 angenommenen Rule 10b5-1 Handelsplans.

  • Optionsausübung (Code M): Rolph übte 12.500 Optionen zum Ausübungspreis von 21,09$ aus und wandelte diese in eine gleiche Anzahl von Stammaktien um.
  • Verkäufe am offenen Markt: Unmittelbar nach der Ausübung verkaufte er dieselben 12.500 Aktien in drei Tranchen: 10.634 Aktien zu einem gewichteten Durchschnittspreis von 50,932$, 1.825 Aktien zu 51,996$ und 41 Aktien zu 52,617$.
  • Netto-Besitz: Direkt gehaltene Aktien verringerten sich von 179.624 auf 167.124 (-7,0%). Derivative Bestände umfassen 19.933 ausgeübte, aber nicht realisierte Optionen (Ausübungspreis 21,09$, Ablauf 12.12.2029).

Die Transaktion brachte rund 640.000$ Bruttoerlös ein und hinterlässt Rolph eine bedeutende Aktienposition. Da sich Ausübung und Verkauf mengenmäßig ausgleichen, wurde Bargeld realisiert, aber die Gesamtzahl der Unternehmensaktien bleibt unverändert. Die Einreichung gibt keine Motive über den vorab festgelegten Handelsplan hinaus an und enthält keine operativen oder Gewinninformationen.

Positive
  • None.
Negative
  • Insider net sale of 12,500 shares (â‰�7% of personal stake) could be interpreted as a minor bearish signal, though mitigated by 10b5-1 plan.

Insights

TL;DR Neutral: CSO exercised options and sold equivalent shares; modest reduction in insider stake, limited signalling impact.

Rolph’s net sale of 12,500 shares represents about 7% of his direct holdings and far less than 1% of Akero’s public float, so market impact is expected to be negligible. Because the trades were executed under a pre-scheduled Rule 10b5-1 plan, the informational value regarding management’s outlook is diminished. Retention of 167k shares plus nearly 20k vested options indicates continued alignment with shareholders. Overall, this is a routine liquidity event rather than a strategic shift.

TL;DR Routine Form 4; compliant with Rule 10b5-1, no red flags.

The filing demonstrates procedural adherence: timely reporting, explicit mention of the 10b5-1 plan, and weighted-average sale disclosures with undertaking to provide full breakdowns. No amendments or late filings are noted. Such governance transparency mitigates potential concerns typically associated with insider selling.

Akero Therapeutics, Inc. (AKRO) Comunicazione Form 4: Il Chief Scientific Officer Timothy Rolph ha riportato l'esercizio di opzioni e la vendita correlata di azioni il 07/07/2025, nell'ambito di un piano di trading Rule 10b5-1 adottato il 12/08/2024.

  • Esercizio opzioni (Codice M): Rolph ha esercitato 12.500 opzioni al prezzo di esercizio di 21,09$, convertendole in un pari numero di azioni ordinarie.
  • Vendite sul mercato aperto: Immediatamente dopo l'esercizio ha venduto le stesse 12.500 azioni in tre tranche: 10.634 azioni a un prezzo medio ponderato di 50,932$, 1.825 azioni a 51,996$ e 41 azioni a 52,617$.
  • Proprietà netta: Le azioni detenute direttamente sono diminuite da 179.624 a 167.124 (-7,0%). Le detenzioni di derivati ammontano a 19.933 opzioni maturate ma non esercitate (prezzo di esercizio 21,09$, scadenza 12/12/2029).

L'operazione ha prodotto circa 640.000$ di proventi lordi, lasciando comunque a Rolph una posizione azionaria significativa. Poiché gli importi di esercizio e vendita si compensano, è stato realizzato un incasso in contanti ma il numero totale di azioni della società non è cambiato. La comunicazione non specifica motivazioni oltre al piano di trading predefinito e non contiene informazioni operative o sugli utili.

Akero Therapeutics, Inc. (AKRO) Presentación del Formulario 4: El Director Científico Timothy Rolph reportó el ejercicio de opciones y la venta relacionada de acciones el 07/07/2025, bajo un plan de negociación Rule 10b5-1 adoptado el 12/08/2024.

  • Ejercicio de opciones (Código M): Rolph ejerció 12.500 opciones a un precio de ejercicio de 21,09$, convirtiéndolas en un número igual de acciones ordinarias.
  • Ventas en mercado abierto: Inmediatamente después del ejercicio vendió las mismas 12.500 acciones en tres tramos: 10.634 acciones a un precio promedio ponderado de 50,932$, 1.825 acciones a 51,996$ y 41 acciones a 52,617$.
  • Propiedad neta: Las acciones en propiedad directa disminuyeron de 179.624 a 167.124 (-7,0%). Las tenencias derivadas son 19.933 opciones ejercitables no ejercidas (precio de ejercicio 21,09$, vencimiento 12/12/2029).

La transacción generó aproximadamente 640.000$ en ingresos brutos, dejando a Rolph con una posición accionaria considerable. Debido a que los montos de ejercicio y venta se compensan, se obtuvo efectivo pero el número total de acciones de la empresa no cambió. La presentación no revela motivos más allá del plan de negociación preestablecido y no contiene información operativa o de ganancias.

Akero Therapeutics, Inc. (AKRO) Form 4 제출: 최고 과학 ì±…ìž„ìž� Timothy Rolphê°€ 2025ë…� 7ì›� 7ì¼ì— 2024ë…� 8ì›� 12ì� 채íƒë� Rule 10b5-1 거래 계íšì—� ë”°ë¼ ì˜µì…˜ 행사 ë°� ê´€ë � ì£¼ì‹ ë§¤ë„ë¥� 보고했습니다.

  • 옵션 행사 (코드 M): RolphëŠ� 행사 ê°€ê²� $21.09ì—� 12,500ê°œì˜ ì˜µì…˜ì� 행사하여 ë™ì¼í•� ìˆ˜ì˜ ë³´í†µì£¼ë¡œ 전환했습니다.
  • 공개 시장 매ë„: 행사 ì§í›„ ë™ì¼í•� 12,500주를 ì„� 차례ì—� ê±¸ì³ ë§¤ë„했습니다: 10,634주를 가중í‰ê·� $50.932ì—�, 1,825주를 $51.996ì—�, 41주를 $52.617ì—� 매ë„했습니다.
  • ìˆ� 소유ê¶�: ì§ì ‘ 보유 주ì‹ì€ 179,624주ì—ì„� 167,124주로 7.0% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. íŒŒìƒ ìƒí’ˆ 보유ëŠ� 행사 ê°€ê²� $21.09, 만기 2029ë…� 12ì›� 12ì¼ì¸ 19,933ê°œì˜ í–‰ì‚¬ 가능한 옵션입니ë‹�.

ì´ë²ˆ 거래ë¡� ì•� 64ë§� 달러ì� ì´� 수ìµì� 얻었으며, RolphëŠ� 여전íž� ìƒë‹¹í•� ì§€ë¶„ì„ ë³´ìœ í•˜ê³  있습니다. 행사와 ë§¤ë„ ìˆ˜ëŸ‰ì� ìƒì‡„ë˜ì–´ í˜„ê¸ˆì€ ì‹¤í˜„ë˜ì—ˆìœ¼ë‚˜ 회사ì� ì´� ì£¼ì‹ ìˆ˜ëŠ” ë³€ë™ì´ 없습니다. 제출 서류ì—는 사전 계íšë� 거래 ê³„íš ì™¸ì— ë™ê¸°ê°€ 공개ë˜ì§€ 않았으며, ìš´ì˜ ë˜ëŠ” ìˆ˜ìµ ì •ë³´ëŠ� í¬í•¨ë˜ì–´ 있지 않습니다.

Akero Therapeutics, Inc. (AKRO) Dépôt du Formulaire 4 : Le directeur scientifique Timothy Rolph a déclaré l'exercice d'options et la vente d'actions associée le 07/07/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 12/08/2024.

  • Exercice d'options (Code M) : Rolph a exercé 12 500 options au prix d'exercice de 21,09$, les convertissant en un nombre égal d'actions ordinaires.
  • Ventes sur le marché libre : Immédiatement après l'exercice, il a vendu les mêmes 12 500 actions en trois tranches : 10 634 actions à un prix moyen pondéré de 50,932$, 1 825 actions à 51,996$ et 41 actions à 52,617$.
  • Propriété nette : Les actions détenues directement ont diminué de 179 624 à 167 124 (-7,0%). Les avoirs dérivés comprennent 19 933 options acquises mais non exercées (prix d'exercice 21,09$, expiration 12/12/2029).

La transaction a généré environ 640 000$ de produit brut, tout en laissant à Rolph une position significative en actions. Comme les montants d'exercice et de vente se compensent, du liquidité a été réalisée mais le nombre total d'actions de la société reste inchangé. Le dépôt ne révèle pas de motif au-delà du plan de négociation préétabli et ne contient pas d'informations opérationnelles ou sur les bénéfices.

Akero Therapeutics, Inc. (AKRO) Form 4 Einreichung: Chief Scientific Officer Timothy Rolph meldete am 07.07.2025 die Ausübung von Optionen und den damit verbundenen Verkauf von Aktien im Rahmen eines am 12.08.2024 angenommenen Rule 10b5-1 Handelsplans.

  • Optionsausübung (Code M): Rolph übte 12.500 Optionen zum Ausübungspreis von 21,09$ aus und wandelte diese in eine gleiche Anzahl von Stammaktien um.
  • Verkäufe am offenen Markt: Unmittelbar nach der Ausübung verkaufte er dieselben 12.500 Aktien in drei Tranchen: 10.634 Aktien zu einem gewichteten Durchschnittspreis von 50,932$, 1.825 Aktien zu 51,996$ und 41 Aktien zu 52,617$.
  • Netto-Besitz: Direkt gehaltene Aktien verringerten sich von 179.624 auf 167.124 (-7,0%). Derivative Bestände umfassen 19.933 ausgeübte, aber nicht realisierte Optionen (Ausübungspreis 21,09$, Ablauf 12.12.2029).

Die Transaktion brachte rund 640.000$ Bruttoerlös ein und hinterlässt Rolph eine bedeutende Aktienposition. Da sich Ausübung und Verkauf mengenmäßig ausgleichen, wurde Bargeld realisiert, aber die Gesamtzahl der Unternehmensaktien bleibt unverändert. Die Einreichung gibt keine Motive über den vorab festgelegten Handelsplan hinaus an und enthält keine operativen oder Gewinninformationen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Benefit Street Partners LLC

(Last) (First) (Middle)
1 MADISON AVENUE,
SUITE 1600

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ALTISOURCE PORTFOLIO SOLUTIONS S.A. [ ASPS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/08/2025 J 62(1) A $0.0000 1,753,107 D
Common Stock 07/08/2025 J 19,011(2) A $0.0000 1,772,118 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On May 21, 2025, Mr. Matthew Winkler, a non-management director of Altisource Portfolio Solutions S.A. ("ASPS" or the "Company") and an employee of Benefit Street Partners, LLC, a registered investment adviser under Section 203 of the Investment Advisers Act of 1940, as amended ("BSP"), received a one-time award of 62 restricted shares of ASPS Common Stock. Pursuant to a Director Fees Assignment Agreement (the "Assignment Agreement"), on July 8, 2025 Mr. Winkler assigned the shares referenced herein to BSP for the ratable benefit of the investment funds and accounts managed by BSP and/or its advisory affiliates that own shares of the Company.
2. On May 21, 2025, Mr. Winkler was granted 19,011 restricted share units ("RSUs") as compensation for his role as a non-management director of the Company for the 2025-2026 service year. Pursuant to the Assignment Agreement, on July 8, 2025 Mr. Winkler assigned the RSUs to BSP for the ratable benefit of the investment funds and accounts managed by BSP and/or its advisory affiliates that own shares of the Company.
Remarks:
All share amounts set forth in this Form 4 reflect the Company's 1:8 stock combination effected as of May 28, 2025.
/s/ Enrico Gallo, Authorized Signatory, Benefit Street Partners LLC 07/09/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Akero Therapeutics shares did CSO Timothy Rolph sell?

He sold a total of 12,500 common shares on 07/07/2025.

What was the exercise price of the options exercised by the CSO?

The options were exercised at $21.09 per share.

What prices were the Akero shares sold for?

Weighted-average sale prices were $50.932, $51.996, and $52.617 across three tranches.

How many Akero Therapeutics shares does the insider still own after the transaction?

Timothy Rolph now directly owns 167,124 common shares.

Are the remaining options held by the CSO vested?

Yes, the remaining 19,933 options are vested and exercisable through 12/12/2029.

Was the sale made under a Rule 10b5-1 trading plan?

Yes, the filing states the trades were executed under a 10b5-1 plan adopted on 08/12/2024.
Altisource Portfolio

NASDAQ:ASPS

ASPS Rankings

ASPS Latest News

ASPS Latest SEC Filings

ASPS Stock Data

150.77M
10.80M
28.67%
79.72%
4.53%
AGÕæÈ˹ٷ½ Estate Services
Services-miscellaneous Business Services
Luxembourg
GRAND DUCHY OF LUXEMBOURG